title: Evaluation of Anti Cancer Effects of DPP-4 Inhibitors in Colon Cancer- An Invitro Study.
abstract: BACKGROUND
  Among the oral anti-diabetic drugs, Dipeptidyl peptidase - 4(DPP-4) inhibitor is an emerging class of drugs. Inhibitors of DPP-4 enzyme like Sitagliptin and Vildagliptin have shown Anti-oxidant properties in many studies, both invivo and invitro. It has also been characterized as an apoptotic agent on pancreatic cancer cells. In the following study, Anticancer effect of DPP 4 inhibitors on colon cell lines (HT-29) using MTT assay- {3 -4, 5-dimethyl (thiazol - 2 -yl) -3, 5- dimethyl tetrazolium bromide} assay was elucidated.
  
  
  OBJECTIVE
  To elucidate and compare the anticancer potential of two DPP 4 inhibitors using in-vitro MTT assay on colorectal cell lines (HT-29).
  
  
  METHODS
  We treated HT-29 cell lines with two DPP 4 inhibitors. HT-29 cells were incubated at 37(0)C and drug samples were added in various concentrations and incubated for 24 hours. MTT dye was added to the sample and it was incubated for 4 hours. One ml of DMSO was added Using an Ultraviolet-Spectrophotometer, measurement of absorbance was done at 570nm following which the half maximal inhibitory concentration was graphically estimated in relation to the percentage of viability of the cell and the sample concentration.
  
  
  RESULTS
  We found that both the drugs have shown anticancer activity starting from low to high concentrations when compared with the control using MTT assay. The IC 50 value of Sitagliptin is 31.2 mcg/ml and Vildagliptin is 125 mcg/ml.
  
  
  CONCLUSIONS
  From this study, we found that the drugs have significant Anti-Cancer property, which would probably play a role as cytotoxic agent in tumour cells. Sitagliptin was found to be more potent than Vildagliptin in colon cancer cell lines.
authors.affiliation: Postgraduate Student, Department of Pharmacology, Sri Ramachandra Medical College & Research Institute , Porur, Chennai, India .
authors.forename: C A
authors.initials: CA
authors.lastname: Amritha
authors.affiliation: Associate Professor, Department of Pharmacology, Sri Ramachandra Medical College & Research Institute , Porur, Chennai, India .
authors.forename: Punnagai
authors.initials: P
authors.lastname: Kumaravelu
authors.affiliation: Professor and HOD, Department of Pharmacology, Sri Ramachandra Medical College & Research Institute , Porur, Chennai, India .
authors.forename: D Darling
authors.initials: DD
authors.lastname: Chellathai
keywords: Anticancer activity; Colorectal cell lines; MTT assay
references.citation: J Clin Invest. 2009 Dec;119(12):3613-25
references.pmid: 19920354
references.citation: Cardiovasc Res. 2012 Oct 1;96(1):140-9
references.pmid: 22843705
references.citation: Eur J Pharmacol. 2012 Sep 15;691(1-3):297-306
references.pmid: 22820107
references.citation: J Diabetes Complications. 2012 Jul-Aug;26(4):266-74
references.pmid: 22626875
references.citation: Clin Cancer Res. 2007 Mar 15;13(6):1736-41
references.pmid: 17363526
references.citation: Am J Physiol Heart Circ Physiol. 2010 May;298(5):H1454-65
references.pmid: 20207816
references.citation: Cancer Epidemiol Biomarkers Prev. 2000 Dec;9(12):1271-9
references.pmid: 11142411
references.citation: BMC Endocr Disord. 2003 Apr 10;3(1):3
references.pmid: 12697069
references.citation: Regul Pept. 2005 Jun 15;128(2):159-65
references.pmid: 15780435
references.citation: Circ Cardiovasc Imaging. 2010 Mar;3(2):195-201
references.pmid: 20075143
references.citation: J Clin Endocrinol Metab. 2005 Aug;90(8):4888-94
references.pmid: 15886245
references.citation: Endocrinology. 2011 Sep;152(9):3362-72
references.pmid: 21771884
references.citation: J Med Chem. 2005 Jan 13;48(1):141-51
references.pmid: 15634008
references.citation: Cancer Res. 2003 May 15;63(10):2388-92
references.pmid: 12750256
references.citation: Diabetes. 1995 Jun;44(6):626-30
references.pmid: 7789625
references.citation: J Clin Endocrinol Metab. 2004 May;89(5):2078-84
references.pmid: 15126524